Vanta Bioscience quarterly results and financials

Vanta Bioscience (BSE 540729)₹21.99−1.87%(9 Nov 2026 close)Healthcare Research, Analytics & Technology

Key facts

In the Mar 2026 quarter (consolidated), Vanta Bioscience reported sales of ₹1.52 Cr, up 347.1% from Mar 2025, and net profit of ₹1.92 Cr. For the year to Mar 2026, sales were ₹1.83 Cr and net profit ₹0.10 Cr.

Sales (Mar 2026): ₹1.52 Cr
Net profit (Mar 2026): ₹1.92 Cr
Sales (FY Mar 2026): ₹1.83 Cr
Net profit (FY Mar 2026): ₹0.10 Cr
EPS (Mar 2026): ₹2.70
Borrowings (Mar 2026): ₹38.09 Cr

Company filings, consolidated accounts; latest reported quarter Mar 2026

Vanta Bioscience quarterly results

₹ crore unless stated; each column is a quarter.

Vanta Bioscience Quarterly results
	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026
Sales	3.46	6.20	3.56	1.04	0.34	0.31	1.52
Expenses	5.29	4.11	4.29	1.41	2.00	0.66	0.12
Operating Profit	−1.84	2.07	−0.76	−0.38	−1.69	−0.38	1.37
OPM %	−53.6%	33.4%	−21.1%	−37.9%	−509.1%	−123.4%	91.4%
Other Income	0.67	0.02	0.07	0.05	0.03	0.00	0.17
Interest	3.39	2.84	2.89	2.13	−0.05	0.87	−0.10
Depreciation	1.37	1.55	2.96	1.70	−0.18	0.62	−0.24
Profit before tax	−5.94	−2.31	−6.53	−4.19	−1.42	−1.87	1.89
Tax %	1.5%	−0.9%	−3.1%	−1.2%	−2.1%	−2.7%	−2.7%
Net Profit	−3.91	−0.53	−1.77	−2.06	−1.36	−1.81	1.92
EPS (Rs)	−6.20	−0.85	−2.81	−3.27	−2.16	−2.55	2.70

Vanta Bioscience profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Vanta Bioscience Profit and loss
	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	12.11	13.77	9.84	9.42	5.84	9.74	1.97	1.83
Expenses	8.79	9.37	5.86	5.92	8.20	8.39	6.20	0.79
Operating Profit	3.28	4.36	3.96	3.48	−2.38	1.32	−4.26	1.01
OPM %	27.1%	31.8%	40.2%	36.9%	−41.0%	13.5%	−216.9%	56.0%
Other Income	0.24	0.12	0.02	0.41	0.68	0.10	0.10	0.17
Interest	1.68	1.94	2.13	2.34	5.88	5.73	4.06	0.77
Depreciation	0.72	1.20	1.26	1.33	2.68	4.51	4.43	0.40
Profit before tax	1.11	1.35	0.60	0.23	−10.27	−8.84	−12.65	0.02
Tax %	36.3%	24.6%	23.7%	40.8%	1.7%	−2.5%	5.2%	−900.1%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	0.69	1.00	0.44	0.13	−10.42	−8.60	−13.26	0.10
EPS (Rs)	1.10	1.57	0.70	0.13	−10.25	−3.67	−7.54	0.14
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Vanta Bioscience balance sheet

₹ crore, at each year end.

Vanta Bioscience Balance sheet
	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	6.34	6.33	6.33	6.33	6.33	6.33	6.34	7.13
Reserves	15.95	17.14	17.59	17.69	11.20	8.89	4.11	14.05
Borrowings	13.28	17.39	35.97	44.84	57.22	61.05	70.19	38.09
Other Liabilities	3.52	7.78	9.79	12.59	10.10	9.29	5.40	6.89
Total Liabilities	39.09	48.64	69.68	81.45	84.85	85.56	86.04	66.16
Fixed Assets	17.94	20.78	29.41	36.17	57.33	54.26	55.61	48.11
CWIP	3.71	7.01	19.35	28.46	10.61	12.54	13.48	0.00
Investments	1.96	0.00	0.00	0.00	0.00	0.00	0.00	3.01
Other Assets	15.48	20.85	20.92	16.82	16.91	18.76	16.95	15.04
Inventories	9.27	14.05	9.79	7.27	7.19	7.54	6.53	7.55
Trade receivables	1.55	1.38	2.00	1.12	1.95	3.13	2.49	2.55
Cash & equivalents	3.26	0.19	2.64	0.21	0.09	0.15	0.21	0.13
Total Assets	39.09	48.64	69.68	81.45	84.85	85.56	86.04	66.16

Vanta Bioscience cash flow

₹ crore, for each year.

Vanta Bioscience Cash flow
	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−1.05	2.33	6.98	5.27	−0.62	2.67	−2.42	−5.23
Cash from investing activity	−5.74	−7.60	−22.34	−17.26	−5.92	−3.32	−6.70	−6.88
Cash from financing activity	9.97	2.18	17.84	9.57	6.44	0.70	9.20	12.13
Net cash flow	3.17	−3.06	2.45	−2.42	−0.12	0.05	0.05	0.00
Capex	2.49	0.36	0.87	0.34	28.75	3.41	6.70	0.02
Free cash flow	−3.51	−5.00	−15.24	−11.89	−6.53	−0.62	−9.09	−12.08
CFO / OP %	−32.0%	54.0%	176.0%	152.0%	26.0%	205.0%	57.0%	−512.0%

Vanta Bioscience ratios

Working-capital days and returns, by year.

Vanta Bioscience Ratios
	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	48	38	76	45	124	119	467	514
Inventory days	—	—	—	—	—	—	2,399	—
Days payable	—	—	—	—	—	—	1,820	—
Cash conversion cycle	47	37	75	44	123	118	1,044	513
Working capital days	260	259	90	−136	−164	−218	−2,128	434
ROCE %	—	8.4%	5.2%	3.8%	−5.8%	−4.1%	−11.5%	1.2%

Vanta Bioscience: frequently asked questions

What are the latest quarterly results of Vanta Bioscience?

For the Mar 2026 quarter, Vanta Bioscience reported sales of ₹1.52 Cr, up 347.1% year on year and net profit of ₹1.92 Cr. The operating margin was 91.4%.

What is the annual revenue of Vanta Bioscience?

Vanta Bioscience's sales for the year to Mar 2026 were ₹1.83 Cr.

What is the net profit of Vanta Bioscience?

Net profit for the year to Mar 2026 was ₹0.10 Cr. Earnings per share over the same trailing period were ₹0.14.

How much debt does Vanta Bioscience have?

Vanta Bioscience reported borrowings of ₹38.09 Cr at Mar 2026, against cash and equivalents of ₹0.13 Cr.

What is the free cash flow of Vanta Bioscience?

Cash from operations was −₹5.23 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹12.08 Cr.

Loading…